AIM: To assess whether schistosomiasis coinfection with chronic hepatitis C virus (HCV) influences hepatic fibrosis and pegylated-interferon/ribavirin (PEG-IFN/RIB) therapy response. METHODS: This study was designed as a retrospective analysis of 3596 chronic HCV patients enrolled in the Egyptian National Program for HCV treatment with PEG-IFN/RIB. All patients underwent liver biopsy and anti-schistosomal antibodies testing prior to HCV treatment. The serology results were used to categorize the patients into group A (positive schistosomal serology) or group B (negative schistosomal serology). Patients in group A were given oral antischistosomal treatment (praziquantel, single dose) at four weeks prior to PEG-IFN/RIB. All patients received a 48-wk course of PEG-IFN (PEG-IFNα2a or PEG-IFNα2b)/RIB therapy. Clinical and laboratory follow-up examinations were carried out for 24 wk after cessation of therapy (to week 72). Correlations of positive schistosomal serology with fibrosis and treatment response were assessed by multiple regression analysis. RESULTS: Schistosomal antibody was positive in 27.3% of patients (15.9% females and 84.1% males). The patients in group A were older (P = 0.008) and had a higher proportion of males (P = 0.002) than the patients in group B. There was no significant association between fibrosis stage and positive schistosomal serology (P = 0.703). Early virological response was achieved in significantly more patients in group B than in group A (89.4% vs 86.5%, P = 0.015). However, significantly more patients in group A experienced breakthrough at week 24 than patients in group B (36.3% vs 32.3%, P = 0.024). End of treatment response was achieved in more patients in group B than in group A (62.0% vs 59.1%) but the difference did not reach statistical significance (P = 0.108). Sustained virological response occurred in significantly more patients in group B than in group A (37.6% vs 27.7%, P = 0.000). Multivariate logistic regression analysis of patient data at treatment weeks 48 and 72 showed that positive schistosomal serology was associated with failure of response to treatment at week 48 (OR = 1.3, P = 0.02) and at week 72 (OR = 1.7, P < 0.01). CONCLUSION: Positive schistosomal serology has no effect on fibrosis staging but is significantly associated with failure of response to HCV treatment despite antischistosomal therapy.
AIM: To assess whether schistosomiasis coinfection with chronic hepatitis C virus (HCV) influences hepatic fibrosis and pegylated-interferon/ribavirin (PEG-IFN/RIB) therapy response. METHODS: This study was designed as a retrospective analysis of 3596 chronic HCVpatients enrolled in the Egyptian National Program for HCV treatment with PEG-IFN/RIB. All patients underwent liver biopsy and anti-schistosomal antibodies testing prior to HCV treatment. The serology results were used to categorize the patients into group A (positive schistosomal serology) or group B (negative schistosomal serology). Patients in group A were given oral antischistosomal treatment (praziquantel, single dose) at four weeks prior to PEG-IFN/RIB. All patients received a 48-wk course of PEG-IFN (PEG-IFNα2a or PEG-IFNα2b)/RIB therapy. Clinical and laboratory follow-up examinations were carried out for 24 wk after cessation of therapy (to week 72). Correlations of positive schistosomal serology with fibrosis and treatment response were assessed by multiple regression analysis. RESULTS: Schistosomal antibody was positive in 27.3% of patients (15.9% females and 84.1% males). The patients in group A were older (P = 0.008) and had a higher proportion of males (P = 0.002) than the patients in group B. There was no significant association between fibrosis stage and positive schistosomal serology (P = 0.703). Early virological response was achieved in significantly more patients in group B than in group A (89.4% vs 86.5%, P = 0.015). However, significantly more patients in group A experienced breakthrough at week 24 than patients in group B (36.3% vs 32.3%, P = 0.024). End of treatment response was achieved in more patients in group B than in group A (62.0% vs 59.1%) but the difference did not reach statistical significance (P = 0.108). Sustained virological response occurred in significantly more patients in group B than in group A (37.6% vs 27.7%, P = 0.000). Multivariate logistic regression analysis of patient data at treatment weeks 48 and 72 showed that positive schistosomal serology was associated with failure of response to treatment at week 48 (OR = 1.3, P = 0.02) and at week 72 (OR = 1.7, P < 0.01). CONCLUSION: Positive schistosomal serology has no effect on fibrosis staging but is significantly associated with failure of response to HCV treatment despite antischistosomal therapy.
Entities:
Keywords:
Coinfection; Fibrosis; Hepatitis C virus; Schistosomiasis; Treatment response
Authors: K Frenzel; L Grigull; E Odongo-Aginya; C M Ndugwa; T Loroni-Lakwo; U Schweigmann; U Vester; N Spannbrucker; E Doehring Journal: Am J Trop Med Hyg Date: 1999-06 Impact factor: 2.345
Authors: T El-Khoby; N Galal; A Fenwick; R Barakat; A El-Hawey; Z Nooman; M Habib; F Abdel-Wahab; N S Gabr; H M Hammam; M H Hussein; N N Mikhail; B L Cline; G T Strickland Journal: Am J Trop Med Hyg Date: 2000-02 Impact factor: 2.345
Authors: Ronald E Blanton; Ekram Abdel Salam; Amgad Ehsan; Charles H King; Katrina Ab Goddard Journal: Eur J Hum Genet Date: 2005-05 Impact factor: 4.246
Authors: Sanaa M Kamal; Bradley Turner; Qi He; Jens Rasenack; Leonardo Bianchi; Ahmed Al Tawil; Ahmed Nooman; Mahmoud Massoud; Margaret James Koziel; Nezam H Afdhal Journal: Hepatology Date: 2006-04 Impact factor: 17.425
Authors: Abd Elrazek; Samy Saab; Mahmoud Foad; Elsayed A Elgohary; Mohammad M Sallam; Abdallah Nawara; Ali Ismael; Samar S Morsi; Altaher Salah; Mohamed Alboraie; Akshaya Srikanth Bhagavathula; Marwa Zayed; Hossam Elmasry; Tamer Z Salem Journal: J Transl Int Med Date: 2017-03-31
Authors: Ekram W Abd El-Wahab; Waleed M Abd Elgawad; Mohamed S Abdelaziz; Ashraf I Mikheal; Hanan Z Shatat Journal: Am J Trop Med Hyg Date: 2022-02-28 Impact factor: 3.707
Authors: Abd Elrazek Abd Elrazek; Hamdy Mahfouz; Khaled Abd Elazeem; Mohamed Fakhry; Emad Abd Elrazek; Mahmoud Foad; Mohamed Alboraie; Aly Ragab; Shazly Baghdady; Shymaa E Bilasy; Khaled Salama; Ramy Abdel Masseih; Mohamed Omar Amer; Sayed Hassaneen; Akshaya Srikanth Bhagavathula; Asim Ahmed Elnour; Saif K Al Nuaimi; Abdullah Shehab Journal: Medicine (Baltimore) Date: 2015-12 Impact factor: 1.817